Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: Results from the F rench ARNOS study

A favorable survival effect of phosphate binders ( PBs ) on incident hemodialysis ( HD ) patients was recently reported, but no definitive advantages of calcium‐based or noncalcium‐based PBs have been demonstrated. The aim of this study was to assess the impact of the prescription of PBs using calcium carbonate ( CaCO 3 ) or sevelamer HCl ( SV ) on survival. Baseline PB prescription was recorded using a cross‐sectional analysis of prevalent HD patients from the regional A ssociation R égionale des N éphrologues OSt éodystrophie F rench cohort. A prospective 42‐month survival analysis study was performed. In J uly 2005, 1347 HD patients were included. CaCO 3 , SV , and mixed PBs were prescribed in 55%, 42%, and 24% of cases, respectively, and 26% were not prescribed PBs . Using a Cox proportional model adjusted for several parameters, CaCO 3 use was found to be associated with less mortality ( HR , 0.64 [0.4–0.78]), but not in the case of SV use ( HR , 1.13 [0.92–1.3]). SV prescription was associated with higher mortality than CaCO 3 ( HR , 1.46 [1.1–1.9]). CaCO3 , but not sevelamer prescription, is associated with a favorable effect on survival in a F rench HD population. This novel result can be partly accounted for by the differences in mineral metabolism disorder management that exist between randomized controlled trials and “real life” conditions.